Efficacy and Safety of Prasugrel, Ticagrelor, or Clopidogrel After Percutaneous Coronary Intervention

Which of the oral P2Y purinergic receptor 12 (P2Y) inhibitors provides the optimal efficacy and safety in patients after percutaneous coronary intervention (PCI)?In this systematic review and meta-analysis, there was a lower risk of major adverse cardiovascular events (MACE) with prasugrel compared to clopidogrel and compared to ticagrelor driven by lower myocardial infarction and lower stent thrombosis. There was a higher risk of major bleeding with ticagrelor compared to clopidogrel driven by higher intracranial hemorrhage.These results indicate that prasugrel provides the optimal balance for efficacy and safety in patients after PCI.

Corresponding Author: Sripal Bangalore, MD, MHA, Division of Cardiovascular Medicine, New York University Grossman School of Medicine, 550 1st Ave, New York, NY 10016 (sripalbangalore@gmail.com).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.